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A B S T R A C T
Autophagy is a tightly regulated intracellular self-digestive process involving the lysosomal degrada-
tion of cytoplasmic organelles and proteins. A number of studies have shown that autophagy is dysregulated
in cancer initiation and progression, or cancer cells under various stress conditions. As a catabolic pathway
conserved among eukaryotes, autophagy is regulated by the autophagy related genes and pathways.
MicroRNAs (miRNAs) are small, non-coding endogenous RNAs that may regulate almost every cellular
process including autophagy. And autophagy is also involved in the regulation of miRNAs expression and
homeostasis. Here we reviewed some literatures on the interaction of miRNAs with autophagy and the
application of miRNAs-mediated autophagic networks as a promising target in pre-clinical cancer models.
Furthermore, strategies of miRNAs delivery for miRNAs-based anti-cancer therapy will also be summa-
rized and discussed.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
The word autophagy, from Greek ‘auto’ (self) and ‘phagy’ (eating),
refers to a series of conserved cellular processes. Cells digest their
own cellular contents by lysosomal degradation and recycle the in-
gredients to maintain cell survival through autophagy [1,2]. There
are at least three types of autophagy in eukaryotic cells,
macroautophagy, microautophagy and chaperone-mediated au-
tophagy (CMA), which differ with respect to the mode of delivery
to the lysosome [3]. The term ‘autophagy’ usually indicates
macroautophagy, which is characterized by the engulfment of cy-
toplasm and organelles into double-membrane bound structures,
namely autophagosomes, and delivery to lysosomes. In contrast to
macroautophagy, the lysosome can directly take in cytosolic com-
ponents throughmembrane invagination in microautophagy. While
CMA is only described in mammals, substrate proteins are deliv-
ered into the lysosome by a member of the Hsp70 family of
molecular chaperones in cytosol [4].
Under normal conditions, autophagy remains at a low level for
the maintenance of cellular homeostasis [5]. Stressful conditions,
such as glucose deprivation, hypoxia and so on, can induce au-
tophagy [6]. During stress, autophagy exerts cytoprotective effect
by degradating damaged cellular contents and recycling nutri-
ents. However, hyperactivation of autophagy will lead to cell death
called as ‘autophagic cell death’. The autophagic cell death was in-
troduced in the 1980s to describe dying cells with increased
autophagic markers [7]. Recently, the term‘autophagic cell death’
was deﬁned as a cell death that is mediated by autophagy, which
could be suppressed by pharmacological or genetic inhibition of au-
tophagy [8]. The molecular mechanisms and the function of
autophagic cell death in physiology and pathogenesis remains
unclear and needs further investigation [9].
Dysregulation of autophagy has been implicated in numerous
human disease [10,11], so the tight control of autophagy is very im-
portant. Autophagy is regulated by a complex network that consists
of different signaling pathways and autophagy-related genes (ATGs)
[12]. Recent studies have described that a lot of microRNAs (miRNAs)
are involved in regulation of autophagic process. MiRNAs are a class
of small non-coding RNAs that negatively regulate gene expres-
sion in transcriptional or post-transcriptional level. MiRNAs can bind
to the 3’ untranslated region (UTR) of target messenger RNAs
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(mRNAs), causing translational inhibition or mRNA destabiliza-
tion. MiRNAs have been found to involve in regulating many cellular
processes [13] and human diseases including cancer [14,15]. The
critical role of miRNAs in autophagy would expand our knowl-
edge of the molecular mechanisms of autophagy regulation. On the
other hand, autophagy is also important to maintain miRNA ho-
meostasis. The interaction between autophagy and miRNA is
important and complicated. Here, we have summarized recent ad-
vances of the interaction between autophagy and miRNA, and tried
to explore the possibility of miRNAs-mediated autophagic net-
works as a target for cancer therapy. Moreover, since regulation of
miRNAs is a promising therapy for human cancer in the future, strat-
egies of miRNAs delivery for miRNAs-based anti-cancer therapy will
then be discussed.
Regulation of autophagy by miRNAs
Zhu et al. [16] ﬁrst reported that miR-30a could negatively reg-
ulate autophagic activity. Dual luciferase reporter assay indicated
that miR-30a could bind to the 3’-UTR of Beclin-1 and downregulate
Beclin-1 expression. Furthermore, transfection of miR-30a mimics
can inhibit rapamycin-induced autophagy in T98G cells. Recently,
more miRNAs have been demonstrated to regulate some ATGs and
their regulators at different stages of autophagy: induction, vesicle
nucleation, vesicle elongation, retrieval, and fusion.
First, autophagy induction is initiated by activation of the ULK
complex, which includes ULK1/2, ATG13, FIP200 and ATG101 [17,18].
The ULK1 protein kinase is a key initiator of the autophagic process.
mTOR can phosphorylate ULK1 and mammalian ATG13 (mATG13)
at nutrient rich conditions, which inhibits ULK1 kinase activity.While
under starvation conditions, inactive mTOR allows ULK1 to phos-
phorylate itself, mATG13 and FIP200, leading to further recruitment
of ATG complexes, such as the class III phosphatidylinositol 3-kinase
(PI3KCIII), to initiate autophagy. In melanoma cells, miR-290–295
cluster could inhibit expression of ULK1, and ATG7, then suppress
autophagic cell death induced by glucose starvation [19]. Leucine
deprivation downregulated miR-20a and miR-106b expression via
suppression of their transcription factor c-Myc. Transfection with
miR-20a or miR-106bmimic can inhibit leucine deprivation induced
autophagy in C2C12 myoblasts. And the mechanistic study vali-
dated that miR-20a and miR-106b can directly target ULK1 and
suppress its expression [20]. Isoliquiritigenin, a simple chalcone-
type ﬂavonoid derived from liquorice compounds, induced
chemosensitization, cell cycle arrest and autophagy in multi-drug
resistant MCF7 cells. The mechanic study revealed that miR-25 is
the main target of soliquiritigenin, and miR-25 inhibition led to au-
tophagic cell death by directly increasing ULK1 expression [21]. A
recent study has reported that ULK2, an another upstream au-
tophagy initiator, is a direct target of miR-885-3p [22], so miR-885-
3p might also contribute to the regulation of autophagy.
Second, vesicle nucleation is initiated by activation of the class
III PI3K/Beclin-1 complex. Numerous binding partners of this
complex include Bax-interacting factor-1 (BIF-1), hVPS34, ATG14L,
UV irradiation resistance-associated gene (UVRAG), Rubicon, and
so on. miRNA-30a/b, miRNA-376b, miR-216a, and miR-17-5p can
inhibit Beclin-1 expression, thereby suppressing vesicle nucle-
ation [23–26]. Huang et al. [27] found that Beclin-1 can also be
targeted by miR-519a. Additionally, they reported that miR-630 and
miR-374a can inhibit UVRAG, which interacts with Beclin-1, then
lead to activation of autophagy. ATG14, a critical component of the
class III PI3K/Beclin-1 complex for the nucleation of the
autophagosomal membrane, was identiﬁed as the target of miR-
195 [28]. RAB5A, a small GTPase, can induce autophago-
some formation by its interaction with hVPS34 and Beclin-1.
miRNA-101 can target RAB5A to inhibit autophagy, indicating that
miR-101 modulates autophagy at the step of vesicle nucleation
[29,30].
Third, vesicle elongation requires two ubiquitin-like conjuga-
tion systems: the ATG12-ATG5-ATG16L system and the ATG8-
phosphatidylethanolamine system. The ATG3, ATG4, ATG5, ATG7,
ATG10, ATG12, ATG16L, and microtubule-associated protein 1 light
chain 3 (LC3) are involved in this phase. miR-101 and miR-376b can
negatively regulate the expression of ATG4C and ATG4D [24,29]. miR-
376a had the same seed sequence and consistency targets with miR-
376b such as ATG4C and Beclin-1 [31]. miR-375 inhibited LC3-I to
LC3-II conversion in hepatocellular carcinoma (HCC) cells by tar-
geting ATG7 [32]. miR-17 can reduce ATG7 expression in
glioblastoma cell lines [33]. RAB5A has also been involved in ATG5-
ATG12 conjugation [29]. Therefore, miR-101 may affect both at the
stage of vesicle nucleation and elongation by targeting RAB5A. miR-
204 can regulate autophagy in renal clear cell carcinoma (RCC)
through regulation of LC3B [34]. miR-106B, miR-93, and miR142-
3p modulate autophagy via targeting ATG16L [35,36]. While miR-
30a/c, miR-130a, miR-519a, miR-181a, miR-374a, miR-885-3p,
and miR-630 can suppress autophagy by targeting ATG5-ATG12
conjugation [27,37,38].
Finally, the process of retrieval and fusion is regulated by ATG2,
ATG9, UVRAG and ATG18. A lot of miRNAs are involved in this late
stage of autophagy. ATG2B was identiﬁed as a direct target of miR-
130a [39]. In mammalian cells, miR-34 represses autophagy by
reducing the expression of ATG9 [40]. Jegga et al. [41] analyzed tran-
scriptional and miRNAs-mediated post-transcriptional regulation
of ATGs. They found that miR-130, 98, 124, 204 and 142 are in-
volved in regulation of autophagy-lysosomal pathway genes. UVRAG
is an important molecule in the fusion process. Therefore, miRNAs
targeting UVRAG such as miR-630 and miR-374a, may be involved
in the regulation of the autophagosome–lysosome fusion process
[27].
Besides the miRNAs and their targets described above, there are
also other miRNAs involved in autophagy regulation. Apoptosis re-
pressor with caspase recruit domain (ARC) is identiﬁed to be an anti-
autophagy protein. ARC knockout mice exhibit increased autophagic
activity, while ARC transgenic mice exhibit decreased autophagy ac-
tivity. miR-325 could negatively regulate the translational activity
of ARC, indicating ARC is a target of miR-325 [42]. The suppres-
sion of ARC by miR-325 could enhance autophagic activity in mice
model.
Immunity-related GTPase family M gene (IRGM) can regulate the
innate immune response by modulating autophagy. Bioinformat-
ics analysis revealed the IRGM is a potential target of miR-196 [43].
miR-196-based regulation of IRGM affects the eﬃcacy of au-
tophagy in patients with Crohn’s disease [44].
Histone acetyltransferases (HATs) and deacetylases (HDACs) play
important roles in protein acetylation. ThemiR-206 andmiR-9 could
regulate the expression of HDAC and HAT in Waldenstrom macro-
globulinemia (WM) cells and result in autophagy-dependent cellular
toxicity [45].
BCL-2 can bind to Beclin-1 and inhibit Beclin-1-dependent au-
tophagy. Therefore, miR-182, miR-34a, miR-210, miR-205 and miR-
21 [46–50], via targeting BCL-2, probably regulate autophagy through
BCL-2/Beclin-1-PI3KIII pathway. The protein of p62, also known as
sequestosome 1 (SQSTM1), is one of the selective substrates for au-
tophagy, as well as a scaffold in autophagosomes. The miR-17/20/
93/106 shares the same AAGUGC ‘seed’ region and direct regulates
p62 expression [51], indicating their potential roles in autophagy
regulation. miR-155 induced by hypoxia can enhance autophagy by
targetingmultiple genes inmTOR signaling, including RHEB, RICTOR,
and RPS6KB2 [52]. miR-100 can promote autophagy in hepatocel-
lular carcinoma cells by targeting mTOR and IGF-1R [53].
In summary, the reported miRNAs involved in autophagy are
listed in Table 1 and illustrated in Supplementary Fig. S1.
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Regulation of miRNAs homeostasis by autophagy
miRNAs generally maintain at a low level in cancer, which may
be due to downregulation of important miRNA processing enzymes,
such as Drosha and Dicer, in tumor cells. Inhibition of Dicer by siRNA
reduced LC3-I and LC3-II expression regardless of presence or
absence of the lysosomal inhibitor baﬁlomycin A, indicating au-
tophagy and Dicer presence a feedback loop [39]. Gibbings et al. [57]
ﬁrst reported that the key ingredients of miRNAs biogenesis com-
plexes, Dicer and AGO2, are selectively degraded by NDP52-
mediated autophagy. The autophagy-deﬁcient cells showed increased
AGO2 and Dicer, decreased ability of AGO-binding to miRNAs, and
then decreased expression of miRNAs. They predicted that non-
degradable Dicer–AGO2 complexes may suppress the activity of
active Dicer–AGO2 complexes. The inactive Dicer–AGO2 com-
plexes degraded by autophagy are important for the function of the
Dicer–AGO2 complexes. NDP52-mediated autophagy is essential for
regulation of miRNA activity and homeostasis.
Autophagy is also involved in the regulation of miRNAs-mediated
gene silencing in Caenorhabditis elegans [58]. AIN-1, a key ingredi-
ent of miRNA-induced silencing complex (miRISC), is selectively
degraded by autophagy. In addition to selective degradation of RNA-
induced silencing complex (RISC) components, miRNA can also be
directly degraded by autophagy. Lan et al. [59] demonstrated that
autophagy is down-modulated and negatively correlated with the
expression of miR-224 in hepatitis B virus (HBV)-associated HCC
specimens. Mature miR-224 is speciﬁcally removed by the
autophagosome-lysosome pathway. The pro-autophagy genes gen-
erally have inactive mutations during human cancer development,
in line with the down-regulated level of autophagy in pre-malignant
cells. Decreased autophagic activity may be involved in some on-
cogenic miRNAs upregulation (Fig. 1).
The interaction between autophagy and miRNA is extremely
complex and poorly understood. There are still many unanswered
questions. Many studies have shown that autophagy ﬂuctuates
during the initiation and development of cancers, and plays a par-
adoxical role in different stages of this malignant disease [60–62].
Generally, autophagy may function as a tumor-suppressive mech-
anism in the tumor initial stage, so it is often downregulated through
inactivating mutations in pro-autophagy genes. However, el-
evated autophagy has been observed in many cancer cells under
stressed conditions, such as hypoxia and anti-cancer therapy, sug-
gesting that autophagy may serve as a cytoprotective mechanism
in tumor development stage. The molecular mechanisms of how
cancer cells regulate autophagy accurately for continued growth and
survival are still unclear. When faced with various stresses, cells can
reprogram their gene expression through complicated miRNA-
involved signaling pathways. We can hypothesize that miRNAs may
contribute to ﬂuctuations of autophagy in tumor cells. For example,
recent studies discovered that miR-155 is upregulated by hypoxia
induced autophagy through dysregulation of mTOR pathway in
human nasopharyngeal and cervical cancer cells [52]. The compli-
cated interaction between autophagy and miRNAs needs further
investigation.
Therapeutic potential of miRNAs-mediated
autophagic pathway
Autophagy has been associated with both cell survival and cell
death, but the contribution of autophagy to cancer cell death remains
controversial [63]. Increasing evidence indicate that autophagy is
induced by the multiple anti-cancer therapeutics, including
Table 1
miRNAs involved in autophagy regulation.
MiRNA Target gene References
Autophagy induction
miR-290–295, miR-20a,
miR-106b, and miR-25
ULK1 [19–21]
miR-885-3p ULK2 [22]
Vesicle nucleation
miR-30a, miR-30b, miR-376b,
miR-519a, miR-17-5p, miR-376a,
and miR-216a
BECN1 [16,23–27,
31,54,55]
miR-374a and miR-630 UVRAG [27]
miR-195 ATG14 [28]
miR-101 RAB5A [29]
Vesicle elongation
miR-101, miR-376a, and miR-376b ATG4 [24,29,31]
miR-17 and miR-375 ATG7 [32,33]
miR-204 LC3 [34]
miR-519a ATG10 [27]
miR-106b, miR-93, miR142-3p,
and miR-130a
ATG16L1 [35–37]
miR-181a, miR-374a, and miR-30c ATG5 [27,37,38]
miR-630 and miR-23b ATG12 [27,56]
Retrieval and fusion
miR-130a ATG2B [39]
miR-34 ATG9 [40]
miR-130, miR-98, miR-124,
miR-204, and miR-142
Autophagy-
lysosomal
pathway genes
[41]
Others
miR-325 ARC [42]
miR-196 IRGM [43,44]
miR-206 and miR-9 HDAC and HAT [45]
miR-182, miR-34a, miR-210,
miR-205, and miR-21
BCL-2 [46–50]
miR-17, miR-20, miR-93, and miR-106 SQSTM1 [51]
miR-155, and miR-100 mTOR pathway
genes
[52,53]
Fig. 1. A hypothetical schematic model of autophagy-regulated miRNA expression in tumor development and progression. Decreased level of autophagy occurs during tumor
development. Low autophagic activity may play an important role in upregulation of oncogenic miRNAs and downregulation of tumor suppressive miRNAs. This autophagy-
dependent modulation of miRNAs promotes tumor initiation and progression.
334 Z. Jing et al./Cancer Letters 356 (2015) 332–338
chemotherapy, radiotherapy, and targeted therapy. Most of these
anti-cancer therapeutics activate autophagy to protect cells from
stress-induced damage, thereby promote drug resistance in cancer
cells. On the other hand, emerging studies also reported that anti-
cancer therapy-induced an autophagic cell death. Targeting
autophagy may offer a novel and complex therapeutic strategy for
cancer therapy.
The autophagy regulators RAB1B is a target of miR-502 [64]. The
expression of miR-502 was inversely correlated with the expres-
sion of RAB1B in colorectal tumor tissues. Over expression of miR-
502 can suppress autophagy and proliferation in colon cancer cells,
indicating miR-502 is a new target for colon cancer. In hypoxic con-
ditions, miR-375 inhibits autophagy and HCC cells growth by
reducing expression of ATG7 [32]. miR-101 is a key regulator of au-
tophagy through regulation RAB5A, ATG4C, and ATG4D. Inhibition
of autophagy by miR-101 synergizes HCC cells to doxorubicin and
ﬂuorouracil treatment [65]. In another study, miR-101-mediated in-
hibition of autophagy can enhance cisplatin-induced apoptosis in
HCC cells [66]. Thus, modulation of autophagy by miR-101 repre-
sents a new cancer therapeutic target.
Additionally, modulation of autophagy by miRNAs can reverse
anti-cancer therapy resistance [54]. Through inhibition of Beclin-
1-dependent autophagy, miR-30a can increase the sensitivity of
imatinib in chronic myeloid leukemia (CML) cells and cisplatin in
tumor cells in vitro and in vivo [55,67]. Furthermore, miR-30d, miR-
205, miR-199a-5p, miR-101, and miR-885-3p mediated inhibition
of autophagy can increase cisplatin sensitivity in tumor cells
[22,66,68–70]. miR-101 can effectively reverse tamoxifen-induced
autophagy and sensitize breast cancer cells to tamoxifen [29].
miR-21 is upregulated in radio-resistant glioblastoma cells. In-
hibition of miR-21 sensitizes glioblastoma cells to radiotherapy
induced apoptosis viamodulation of autophagy [71]. Downregulation
of miR-21 can also increase the chemosensitivity of leukemia cells
to etoposide or doxorubicin [72]. ATG12-mediated autophagy is a
critical mechanism of radioresistance. In radioresistant pancreatic
cancer cells, miR-23b is downregulated. Ectopic over-expression of
miR-23b suppressed radiation-induced autophagy by direct target-
ing ATG12 and sensitized pancreatic cancer cells to radiotherapy
[56]. ATG7, an essential autophagy related gene for vesicle elonga-
tion, is a target of miR-17. Comincini et al. [33] reported that anti-
miR-17 activated autophagy and sensitized glioblastoma cells to
radiation and temozolomide therapy.
The role of miRNAs-mediated autophagy in cancer therapy is con-
troversial. Therefore, miRNAs-mediated autophagy as a therapeutic
strategy should be designed according to the speciﬁc tumor type,
tumor environment and the disease context.
miRNAs-based therapeutic strategies
There are two major approaches to target miRNA: miRNA re-
duction andmiRNA replacement. miRNA can regulate the expression
of multiple genes, so miRNAs-based therapeutic strategies can affect
many cell biological processes, including proliferation, apoptosis,
cell differentiation, and so on. The miRNAs-based therapeutic strat-
egies might be more favorable than the conventional therapeutic
strategies.
Chemicals and drugs modulate miRNA expression
Several chemicals and drugs can regulate the expression of
miRNAs via targeting miRNA encoding genes, miRNA maturation
or degradation process. Shum and colleagues developed a simple
image-based strategy to screen for inhibitors of miRNAs [73]. The
authors developed a miR-21 synthetic mimic together with an EGFP
based reporter cell line, in which the expression of EGFP is under
the control of miR-21. Approximately 7000 compounds were
screened and six compounds were identiﬁed as potential inhibi-
tors of miR-21. This strategy offers a new opportunity to identify
novel and speciﬁc inhibitors for other distinct miRNAs with poten-
tial use to modulate autphagy. Bose et al. [74] used a molecular
beacon based method to screen effective inhibitors of miR-27a.
They found that ﬁve aminoglycosides were able to antagonize miR-
27a’s function from 14 aminoglycosides screened. The identiﬁed
inhibitors interfered with Dicer function. However, most identi-
ﬁed inhibitors have not been studied extensively in vivo, thus
the eﬃcacy and safety of these inhibitors need to be further
investigated.
Several groups have reported that drugs treatment can alter the
expression of miRNAs. Imatinib can induce expression of miR-203
resulting in growth inhibition of BCR-ABL1-positive leukemic cells
[75]. All trans-retinoic acid (ATRA) can induce acute myeloid leu-
kemia (AML) cell differentiation by regulating miR-663 expression
[76]. Many of the biological effects of anti-cancer drugs may be me-
diated by its effect on modulation of the miRNAs’s expression. So
it is theoretically reasonable to develop a series of pharmacy with
the function of modulating expression of speciﬁc miRNAs, which
play important roles in autophagy regulation as mentioned above.
Anti-miRNA oligonucleotides
Antagomirs, an antisense oligonucleotide, can directly bind to
a target miRNA and block its function [77]. To increase stability and
eﬃciency, the antagomir need to be modiﬁed with 2-O-methyl-
group (OME), 2-O-methyoxyethyl (MOE), or locked nucleic acid (LNA).
The antagomirs modiﬁed withMOE have a higher aﬃnity and speci-
ﬁcity to RNAs compared with antagomirs modiﬁed with OME [78].
LNA modiﬁcation can extremely increase antagomir’s stability and
aﬃnity. The LNA-modiﬁed anti-miR-122 has been shown to sup-
press liver-expressed miR-122 signiﬁcantly and lead to long-term
suppression of HCV infection in liver of chimpanzees [79]. Murphy
et al. [80] reported that 8-mer LNA-modiﬁed anti-miR oligonucle-
otides inhibited miR-17, 20a, 106b, 93, 19a, and 19b-1 expression
and prolonged the survival of mice in the murine medulloblas-
toma model. The major disadvantage of anti-miR oligonucleotides
is its unspeciﬁty. They may affect endogenous RNA species other
than the target miRNAs.
miRNA Mimics
miRNA mimics are synthetic 18–22 nucleotide oligonucle-
otides designed tomimic nativemiRNAs. miRNAmimics are identical
to the endogenousmiRNAs and target the samemRNAs. Studies have
shown that a two-stranded oligonucleotide is 100–1000 fold more
effective than a single-stranded mimic [81]. It has been reported
that double-stranded Let-7 mimics can suppress the growth, mi-
gration, as well as cell cycle progression of lung cancer cell lines
in vitro [82]. miR-34a synthetic mimics triggered growth inhibi-
tion and apoptosis in multiple myeloma cells with downregulating
canonic targets BCL-2, CDK6, and NOTCH1 in vitro and in vivo [83].
In mouse xenograft models, relevant tumor growth inhibition and
survival improvement were observed in animals treated with miR-
34a mimics in the absence of systemic toxicity. The limitations of
miRNA mimic include potential off-target effects, susceptibility to
nuclease degradation, and affect the normal functions of cells.
In summary, the miRNAs-based therapeutic strategies are
illustrated in Fig. 2.
miRNA delivery systems
miRNA-based therapy need to have selective and accurate de-
livery systems to increase the therapeutic potential and reduce
possible systemic toxicity.
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Viral-based delivery system
Adeno-associated viruses (AAV) are often used for delivering
miRNAs. The advantages of these vectors are that AAV vectors do
not integrate into the genome and can be removed eﬃciently with
minimal toxicity. AAV-based therapeutic strategies are in pre-
clinical and clinical studies, including the use of novel tissue-
speciﬁc promoters, and AAV capsid mutants and chimeras [84].
Tissue-speciﬁc promoters can be used to ensure eﬃcient delivery
to the speciﬁc organ. AAV-based miR-26a therapy inhibits cancer
cell proliferation and increases apoptosis in a mouse model of liver
cancer without signiﬁcant systemic toxicity [85].
Lipid-based delivery system
Liposome is one of the majorly used transfection reagents. Lipid-
based system have been shown to have increased cellular uptake,
lifetime in circulation and ability to penetrate into the tumor [86].
Using chemically synthesized miR-34a and a lipid-based delivery
vehicle eﬃciently inhibited tumor growth without liver or kidney
toxicity and immune response in a mouse lung tumor model [87].
Lipid-based delivery of miR-107 mimics effectively decreased tu-
morigenicity of head and neck squamous cell carcinoma in mouse
xenograft models [88]. Li et al. [89] developed a T-VISA-miR-34a
plasmid, to speciﬁcally over-expression of miR-34a in breast cancer
cells by an hTERT promoter. In an orthotopic mouse model of breast
cancer, T-VISA-miR-34a liposomal complex can strikingly sup-
press tumor proliferation, prolong survival without systemic toxicity.
Nanocarriers delivery system
With nanocarriers, drugs can be encapsulated within vehicles
based on similar building blocks. Incorporation of PEI into poly(d,l-
lactide-co-glycolide) (PLGA) particles has good biocompatibility and
biodegradability and can be useful in the gene delivery. Liang et al.
[90] developed a PLGA/PEI nanoparticle formiRNA delivery in human
hepatocellular carcinoma cells. They reported that PLGA-based gene
delivering nanoparticle enhanced suppression effect of miR-26a in
HePG2 cells. Minjun et al. [91] developed protamine sulphate (PS)–
nanodiamond (ND) nanoparticles to deliver miRNA-203 into
esophageal cancer cells. Griveau et al. [92] reported that deliver-
ing miR-21 antagomir with a lipid-based nanoparticle system
enhanced radio-sensitivity in glioblastoma cells.
In summary, the advantages and disadvantages of differentmiRNA
delivery systems are listed in Table 2. Many miRNAs with the po-
tential function to regulate autophagy are dysregulated in human
cancers. Targeting these miRNAs for autophagy modulation pres-
ents a promising therapeutic strategy for cancer therapy. Using
miRNA mimics or inhibitors, we can inhibit cytoprotective effect or
promote cytotoxic effect of autophagy in a variety of cancers. Fur-
thermore, modulation of autophagy by miRNAs-based therapy can
also be used as an adjuvant therapy to circumvent cancer drug or
radiation resistance.
Conclusions and perspectives
Autophagy is a basic catabolic process involved in cancer cell’s
survival. miRNA-mediated regulation of autophagy related gene is
an essential part of the molecular mechanisms in autophagy. Thus
a thorough understanding of the interaction between autophagy and
miRNAs is important to develop amiRNAs-based therapy. Until now,
the relationship between autophagy and miRNAs is mainly inves-
tigated in tumor cells, but their interaction in normal cells remains
unclear. Further investigation in normal cells will contribute to reveal
the function of miRNAs-mediated autophagy in both physiologi-
cal and pathological conditions.
However, there is still a long way to go before the clinical ap-
plication of miRNAs-based therapeutic strategies. The main issues
of this novel therapeutic method are as follows. The effect of
chemical modiﬁcation on miRNA mimics on its biological activity,
the techniques for eﬃciently delivery of miRNA mimics or miRNA
antagomirs in vivo, and the off-target effects of miRNAs-
based therapeutic strategies. All these questions need to be further
investigated.
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Fig. 2. miRNAs-based therapeutic strategies. Chemical miRNA inhibitors can reg-
ulate miRNA expression at the transcriptional level; antisense oligonucleotides can
bind to a target miRNA and block it; miRNA mimics can restore the downregulated
miRNA expression.
Table 2
Advantages and disadvantages of miRNA delivery systems.
Methods Advantages Disadvantages
Viral-based delivery system Safe; long-term expression; high eﬃciency Elicit immune response; off-target effects
Lipid-based delivery system Safe; stability; high eﬃciency Off-target effects; highly immunogenic
Nanocarriers delivery system High eﬃciency; safe; low immunogenic; stability; relatively slow release rate Complex formulation
336 Z. Jing et al./Cancer Letters 356 (2015) 332–338
Appendix: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.canlet.2014.09.039.
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